89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) by Carolyn Helms | May 23, 2023 | Portfolio News
Quanta Therapeutics Raises Over $50 Million in Series D Financing to Advance its Pipeline of KRAS Inhibitors by Carolyn Helms | May 22, 2023 | Portfolio News
Endogenex™ Appoints Christopher Sorli as Chief Medical Officer by Carolyn Helms | May 18, 2023 | Portfolio News
CG Oncology Announces New Phase 2 Data with Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA® (pembrolizumab) in BCG-Unresponsive NMIBC by Carolyn Helms | May 1, 2023 | Portfolio News
Theseus Pharmaceuticals Initial Dose Escalation Results from Ongoing Phase 1/2 Trial of THE-630 Accepted for Online Publication at 2023 ASCO Annual Meeting by Carolyn Helms | Apr 26, 2023 | Portfolio News
